Merck shares fall as 2026 guidance disappoints despite solid Q4 results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Merck (MRK) PT Raised to $132 at BofA Securities
February 4, 2026 5:48 AM ESTBofA Securities analyst Tim Anderson raised the price target on Merck (NYSE: MRK) to $132.00 (from $124.00) while maintaining a Buy rating.
The analyst comments "Post 4Q, we reduce our MRK 2026 sales and EPS to reflect greater conservatism around some LOE products, US... More
